Cash flow Arch Biopartners Inc.

Equities

ACHFF

CA03938C1041

Pharmaceuticals

Market Closed - OTC Markets Other stock markets 19:04:51 13/03/2026 GMT			5-day change	1st Jan Change
0.4975 ^USD	-4.16%		-13.70%	-43.68%

03-03	Arch Biopartners Inc. Reports Earnings Results for the First Quarter Ended December 31, 2025	CI
02-09	Arch Biopartners Scientists Publish New Data Linking the Cytokine IL-32 to Inflammation and Diabetic Kidney Disease	CI

b8132e678c8e5e56.D3EtwzvCw14DI9Q8bXnK3s9d6O5rprNMv9SYBagoUaM.SRNjlgr1pmlSe6QRFw685q4WkqUlltQF5b-gVp1RCOtNFR-HXIuZbnJLnQ

Published financial data: ARCH BIOPARTNERS INC.

Annual

Quarterly

Halfyear

YTD

LTM

Fiscal Period: September	2021	2022	2023	2024	2025
Revenues	3.89M	965K	1.98M	2.12M	276K
Total Revenues	3.89M	965K	1.98M	2.12M	276K
Cost of Goods Sold, Total	4.04M	1.47M	2.11M	3.78M	209K
Gross Profit	-150K	-503K	-129K	-1.66M	67.44K
Selling General & Admin Expenses, Total	560K	469K	809K	947K	986K
Stock-Based Compensation (IS)	110K	24.98K	1.96M	853K	216K
Other Operating Expenses, Total	670K	494K	2.77M	1.8M	1.2M
Operating Income	-819K	-997K	-2.9M	-3.46M	-1.13M
Interest Expense, Total	-273K	-309K	-359K	-389K	-258K
Interest And Investment Income	-	-	16.53K	4.07K	-
Net Interest Expenses	-273K	-309K	-342K	-385K	-258K
Currency Exchange Gains (Loss)	-4.86K	-18.49K	11.9K	15.94K	-52.93K
Other Non Operating Income (Expenses)	-72.16K	-82.93K	-100K	-95.31K	-107K
EBT, Excl. Unusual Items	-1.17M	-1.41M	-3.33M	-3.92M	-1.55M
EBT, Incl. Unusual Items	-1.17M	-1.41M	-3.33M	-3.92M	-1.55M
Earnings From Continuing Operations	-1.17M	-1.41M	-3.33M	-3.92M	-1.55M
Net Income to Company	-1.17M	-1.41M	-3.33M	-3.92M	-1.55M
Net Income - (IS)	-1.17M	-1.41M	-3.33M	-3.92M	-1.55M
Net Income to Common Incl Extra Items	-1.17M	-1.41M	-3.33M	-3.92M	-1.55M
Net Income to Common Excl. Extra Items	-1.17M	-1.41M	-3.33M	-3.92M	-1.55M
Per Share Items
Net EPS - Basic	-0.02	-0.02	-0.05	-0.06	-0.02
Basic EPS - Continuing Operations	-0.02	-0.02	-0.05	-0.06	-0.02
Basic Weighted Average Shares Outstanding	61.32M	62.16M	62.47M	63.38M	65.6M
Net EPS - Diluted	-0.02	-0.02	-0.05	-0.06	-0.02
Diluted EPS - Continuing Operations	-0.02	-0.02	-0.05	-0.06	-0.02
Diluted Weighted Average Shares Outstanding	61.32M	62.16M	62.47M	63.38M	65.6M
Normalized Basic EPS	-0.01	-0.01	-0.03	-0.04	-0.01
Normalized Diluted EPS	-0.01	-0.01	-0.03	-0.04	-0.01
Supplemental Items
EBITA	-819K	-997K	-2.9M	-3.46M	-1.13M
EBIT	-819K	-997K	-2.9M	-3.46M	-1.13M
Normalized Net Income	-731K	-880K	-2.08M	-2.45M	-970K
Interest on Long-Term Debt	172K	205K	197K	179K	255K
Supplemental Operating Expense Items
Marketing Expenses	41.06K	19.73K	7.19K	8.42K	83.01K
Selling and Marketing Expenses	41.06K	19.73K	7.19K	8.42K	83.01K
General and Administrative Expenses	297K	241K	382K	395K	469K
Research And Development Expense From Footnotes	3.78M	1.27M	1.94M	3.7M	-9.52K
Stock-Based Comp., Other (Total)	110K	24.98K	1.96M	853K	216K
Total Stock-Based Compensation	110K	24.98K	1.96M	853K	216K

Fiscal Period: September	2021	2022	2023	2024	2025
Assets
Cash And Equivalents	448K	506K	831K	2.97K	2.1K
Short Term Investments	-	-	-	-	-
Total Cash And Short Term Investments	448K	506K	831K	2.97K	2.1K
Accounts Receivable, Total	1.85M	-	-	725K	-
Other Receivables	349K	87.23K	297K	175K	77.74K
Total Receivables	2.2M	87.23K	297K	899K	77.74K
Prepaid Expenses	19.32K	28.06K	43.03K	33.33K	24.68K
Total Current Assets	2.67M	622K	1.17M	936K	105K
Total Assets	2.67M	622K	1.17M	936K	105K
Liabilities
Accounts Payable, Total	962K	489K	393K	2.35M	1.04M
Accrued Expenses, Total	425K	190K	172K	42.92K	-
Short-term Borrowings	1.8M	-	1.71M	2.27M	2.84M
Current Portion of Long-Term Debt	-	2.1M	2.6M	500K	-
Unearned Revenue Current, Total	-	-	1.1M	118K	104K
Total Current Liabilities	3.19M	2.78M	5.98M	5.28M	3.99M
Long-Term Debt	3.36M	2.31M	704K	-	-
Total Liabilities	6.55M	5.09M	6.68M	5.28M	3.99M
Common Stock, Total	14.76M	15.55M	15.88M	17.42M	20.35M
Additional Paid In Capital	4.68M	4.7M	6.66M	7.51M	6.6M
Retained Earnings	-23.32M	-24.72M	-28.05M	-31.97M	-33.52M
Comprehensive Income and Other	-	-	-	2.69M	2.69M
Total Common Equity	-3.88M	-4.47M	-5.51M	-4.35M	-3.88M
Total Equity	-3.88M	-4.47M	-5.51M	-4.35M	-3.88M
Total Liabilities And Equity	2.67M	622K	1.17M	936K	105K
Supplemental Items
ECS Total Shares Outstanding on Filing Date	61.36M	62.4M	62.76M	64.94M	66.93M
ECS Total Common Shares Outstanding	61.96M	62.33M	62.6M	64.65M	66.11M
Book Value / Share	-0.06	-0.07	-0.09	-0.07	-0.06
Tangible Book Value	-3.88M	-4.47M	-5.51M	-4.35M	-3.88M
Tangible Book Value Per Share	-0.06	-0.07	-0.09	-0.07	-0.06
Total Debt	5.16M	4.41M	5.02M	2.77M	2.84M
Net Debt	4.72M	3.91M	4.18M	2.77M	2.84M
Account Code - Inventory Valuation	3	3	3	3	3

Fiscal Period: September	2021	2022	2023	2024	2025
Net Income	-1.17M	-1.41M	-3.33M	-3.92M	-1.55M
Other Operating Activities, Total	-1.81M	1.89M	3.09M	1.59M	-31.34K
Cash from Operations	-2.98M	479K	-234K	-2.33M	-1.58M
Short Term Debt Issued, Total	2.2M	-	-	-	-
Long-Term Debt Issued, Total	-	-	1.5M	350K	338K
Total Debt Issued	2.2M	-	1.5M	350K	338K
Short Term Debt Repaid, Total	-425K	-	-	-	-
Long-Term Debt Repaid, Total	-45.5K	-791K	-1.07M	-210K	-
Total Debt Repaid	-470K	-791K	-1.07M	-210K	-
Issuance of Common Stock	1.05M	370K	128K	1.36M	1.25M
Other Financing Activities, Total	-	-	-	-	-
Cash from Financing	2.78M	-421K	559K	1.5M	1.58M
Net Change in Cash	-205K	58.11K	325K	-828K	-868
Supplemental Items
Cash Interest Paid	74.35K	79.11K	2.59K	2.64K	-
Levered Free Cash Flow	-2.54M	606K	684K	-1.29M	-1.19M
Unlevered Free Cash Flow	-2.37M	799K	909K	-1.05M	-1.03M
Change In Net Working Capital	1.96M	-1.4M	-761K	-256K	537K
Net Debt Issued / Repaid	1.73M	-791K	431K	140K	338K

Fiscal Period: September	2021	2022	2023	2024	2025
Profitability
Return on Assets	-30.04	-37.88	-201.92	-205.03	-136.33
Return on Total Capital	-127.43	-101.86	656.48	208.54	54.14
Return On Equity %	30.18	33.71	66.67	79.54	37.74
Return on Common Equity	30.18	33.71	66.67	79.54	37.74
Margin Analysis
Gross Profit Margin %	-3.85	-52.13	-6.5	-78.05	24.44
SG&A Margin	14.41	48.64	40.78	44.61	357.22
EBITA Margin %	-21.08	-103.36	-145.99	-162.86	-411.11
EBIT Margin %	-21.08	-103.36	-145.99	-162.86	-411.11
Income From Continuing Operations Margin %	-30.1	-145.94	-167.71	-184.76	-562.7
Net Income Margin %	-30.1	-145.94	-167.71	-184.76	-562.7
Net Avail. For Common Margin %	-30.1	-145.94	-167.71	-184.76	-562.7
Normalized Net Income Margin	-18.81	-91.21	-104.82	-115.47	-351.69
Levered Free Cash Flow Margin	-65.3	62.8	34.51	-61.01	-431.64
Unlevered Free Cash Flow Margin	-60.9	82.84	45.81	-49.54	-373.17
Asset Turnover
Asset Turnover	2.28	0.59	2.21	2.01	0.53
Short Term Liquidity
Current Ratio	0.84	0.22	0.2	0.18	0.03
Quick Ratio	0.83	0.21	0.19	0.17	0.02
Operating Cash Flow to Current Liabilities	-0.93	0.17	-0.04	-0.44	-0.4
Average Days Payable Outstanding	86.41	180.5	76.27	133.01	2.94K
Long Term Solvency
Total Debt/Equity	-133.01	-98.71	-91.04	-63.71	-73.16
Total Debt / Total Capital	402.97	-7.64K	-1.02K	-175.58	-272.64
LT Debt/Equity	-86.59	-51.73	-12.78	-	-
Long-Term Debt / Total Capital	262.33	-4K	-142.6	-	-
Total Liabilities / Total Assets	245.5	819.16	570.45	564.69	3.81K
EBIT / Interest Expense	-3	-3.22	-8.07	-8.87	-4.39
Growth Over Prior Year
Total Revenues, 1 Yr. Growth %	5.63K	-75.18	105.63	6.97	-87
Gross Profit, 1 Yr. Growth %	-92.94	235.72	-74.35	1.18K	-104.07
EBITA, 1 Yr. Growth %	-81.29	21.69	190.44	19.32	-67.17
EBIT, 1 Yr. Growth %	-81.29	21.69	190.44	19.32	-67.17
Earnings From Cont. Operations, 1 Yr. Growth %	-74.73	20.36	136.3	17.84	-60.39
Net Income, 1 Yr. Growth %	-74.73	20.36	136.3	17.84	-60.39
Normalized Net Income, 1 Yr. Growth %	-74.73	20.36	136.3	17.84	-60.39
Diluted EPS Before Extra, 1 Yr. Growth %	-75.31	18.74	135.14	16.14	-61.74
Total Assets, 1 Yr. Growth %	259.94	-76.7	88.4	-20.11	-88.83
Tangible Book Value, 1 Yr. Growth %	0.37	15.15	23.25	-21.09	-10.72
Common Equity, 1 Yr. Growth %	0.37	15.15	23.25	-21.09	-10.72
Cash From Operations, 1 Yr. Growth %	56.49	-116.09	-148.82	895.91	-32.05
Levered Free Cash Flow, 1 Yr. Growth %	1.71K	-123.87	12.98	-289.14	-8
Unlevered Free Cash Flow, 1 Yr. Growth %	7.77K	-133.76	13.72	-215.68	-2.05
Compound Annual Growth Rate Over Two Years
Total Revenues, 2 Yr. CAGR %	543.44	276.97	-28.56	48.31	-62.7
Gross Profit, 2 Yr. CAGR %	-67.33	-51.33	-7.2	81.48	-27.69
EBITA, 2 Yr. CAGR %	-34.57	-52.28	88	86.16	-37.41
EBIT, 2 Yr. CAGR %	-34.57	-52.28	88	86.16	-37.41
Earnings From Cont. Operations, 2 Yr. CAGR %	-25.24	-44.85	68.64	66.87	-31.68
Net Income, 2 Yr. CAGR %	-25.24	-44.85	68.64	66.87	-31.68
Normalized Net Income, 2 Yr. CAGR %	-25.24	-44.85	68.64	66.87	-31.68
Diluted EPS Before Extra, 2 Yr. CAGR %	-26.89	-45.85	67.09	65.26	-33.34
Accounts Receivable, 2 Yr. CAGR %	646.45	-	-	-	-
Total Assets, 2 Yr. CAGR %	78.98	-8.43	-33.75	22.68	-70.12
Tangible Book Value, 2 Yr. CAGR %	21.34	7.51	19.13	-1.38	-16.07
Common Equity, 2 Yr. CAGR %	21.34	7.51	19.13	-1.38	-16.07
Cash From Operations, 2 Yr. CAGR %	28.52	-49.83	-71.98	120.5	160.14
Levered Free Cash Flow, 2 Yr. CAGR %	59.51	107.78	-48.07	46.18	31.92
Unlevered Free Cash Flow, 2 Yr. CAGR %	59.67	415.56	-38.04	14.69	6.45
Compound Annual Growth Rate Over Three Years
Total Revenues, 3 Yr. CAGR %	-	117.41	208.01	-18.27	-34.11
Gross Profit, 3 Yr. CAGR %	-53.63	-28.97	-60.68	122.78	-48.81
EBITA, 3 Yr. CAGR %	-34.65	-19.54	-12.87	61.56	4.4
EBIT, 3 Yr. CAGR %	-34.65	-19.54	-12.87	61.56	4.4
Earnings From Cont. Operations, 3 Yr. CAGR %	-27.07	-12.38	-10.42	49.65	3.32
Net Income, 3 Yr. CAGR %	-27.07	-12.38	-10.42	49.65	3.32
Normalized Net Income, 3 Yr. CAGR %	-27.07	-12.38	-10.42	49.65	3.32
Diluted EPS Before Extra, 3 Yr. CAGR %	-28.82	-14.06	-11.66	48.02	1.48
Accounts Receivable, 3 Yr. CAGR %	-	-	-	-26.86	-
Total Assets, 3 Yr. CAGR %	46.13	-9.29	16.47	-29.48	-44.8
Tangible Book Value, 3 Yr. CAGR %	65.06	19.24	12.52	3.85	-4.6
Common Equity, 3 Yr. CAGR %	65.06	19.24	12.52	3.85	-4.6
Cash From Operations, 3 Yr. CAGR %	11.47	-35.71	-50.28	-7.87	48.94
Levered Free Cash Flow, 3 Yr. CAGR %	34.97	-15.31	69.59	-20.1	25.28
Unlevered Free Cash Flow, 3 Yr. CAGR %	33.62	-4.88	211.5	-23.7	8.82
Compound Annual Growth Rate Over Five Years
Total Revenues, 5 Yr. CAGR %	-	-	-	86.57	32.38
Gross Profit, 5 Yr. CAGR %	-18.31	-3.81	-38.8	3.37	-49.83
EBITA, 5 Yr. CAGR %	-3.41	-11.73	-0.28	12.54	-23.67
EBIT, 5 Yr. CAGR %	-3.41	-11.73	-0.28	12.54	-23.67
Earnings From Cont. Operations, 5 Yr. CAGR %	2.75	-5.86	1.98	13.38	-19.62
Net Income, 5 Yr. CAGR %	2.75	-5.86	1.98	13.38	-19.62
Normalized Net Income, 5 Yr. CAGR %	2.75	-5.86	1.98	13.38	-19.62
Diluted EPS Before Extra, 5 Yr. CAGR %	-0.06	-8.31	0.14	11.63	-21.07
Accounts Receivable, 5 Yr. CAGR %	-	-	-	85.23	-
Total Assets, 5 Yr. CAGR %	63.69	55.7	6.49	2.35	-32.42
Tangible Book Value, 5 Yr. CAGR %	69.24	51.32	44.87	10.52	0.07
Common Equity, 5 Yr. CAGR %	69.24	51.32	44.87	10.52	0.07
Cash From Operations, 5 Yr. CAGR %	32.48	-8.8	-35.83	5.25	-3.62
Levered Free Cash Flow, 5 Yr. CAGR %	49.25	63.46	-7.89	5.35	53.38
Unlevered Free Cash Flow, 5 Yr. CAGR %	48.29	83.1	-1.74	2.51	102.74